Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As VP Regulatory Affairs

Inovio Pharmaceuticals, Inc. {NASDAQ:  INO} announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs.

Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovio’s regulatory strategies.


Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs

PLYMOUTH MEETING, PA – August 4, 2016 – Inovio Pharmaceuticals, Inc. {NASDAQ:  INO} today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs.


Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovio’s regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovio’s product pipeline.


Dr. J. Joseph Kim, Inovio’s President & CEO, said, “Ami has shown technical excellence and leadership in successfully moving our DNA-based therapy for women’s health, VGX-3100, through its phase II regulatory process. This is now leading to the initiation of phase III for this program before the end of this year. We expect her strategic guidance and counsel to be invaluable as we advance multiple cancer and infectious disease products through the clinical and regulatory process.”


Prior to Inovio, Dr. Brown was Director, Vaccine Operations, at the Sabin Vaccine Institute in Washington, D.C., where she contributed to the early work of the Sabin Vaccine Institute Product Development Partnership (Sabin PDP), an internationally recognized PDP for the creation of safe, effective, low-cost vaccines for tropical infections in developing countries. She had previous experience at the Johns Hopkins Bloomberg School of Public Health’s Center for Immunization Research, the Emory University Department of Medicine, and the Centers for Disease Control and Prevention (CDC) at the National Center for HIV, STD and TB prevention. She began her career at the University of Pennsylvania Department of Pathology and Laboratory Medicine.

She holds a PhD from Johns Hopkins University’s Bloomberg School of Public Health, a Master of Public Health (MPH) degree from Emory University’s Rollins School of Public Health, and a BA in Biology from the University of Pennsylvania.


About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.


For more information, visit


Bernie Hertel

+1 858 410 3101


This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended March 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.